ICON Reports Second Quarter 2021 Results

ICON报告2021年第二季度业绩

2021-07-22 16:00:34 BioSpace

本文共8204个字,阅读需21分钟

Highlights Record net business wins in the quarter of $1,106 million, an increase of 21.6% year on year; a net book to bill of 1.27. Record closing backlog of $10.2 billion, an increase of 12.7% year on year. Quarter 2 reported revenue of $871.2 million representing a year on year increase of 40.5% and 1.5% increase on Quarter 1 2021. Adjusted income from operations* amounted to $132.9 million or 15.3% of revenue, a year on year increase of 77.1%. Adjusted net income attributable to the Group* was $113.2 million or $2.12 per diluted share, compared to $1.20 per share for the equivalent prior year period, an increase of 76.8%. US GAAP income from operations amounted to $112.9 million or 13.0% of revenue, a year on year increase of 98.2%. US GAAP net income attributable to the Group was $73.9 million or $1.38 per diluted share, compared to $0.90 per share for the equivalent prior year period, an increase of 53.3%. Strong cash generation resulting in a record gross cash position of $1,057 million. Days sales outstanding reduced to 35 days from 53 days at June 30, 2020. Net business wins for PRA’s Clinical Research segment for Quarter 2 including reimbursement revenue was approximately $1,191 million; a net book to bill of 1.21. Quarter 2 revenue was approximately $1,047 million, a year on year increase of 43.5%. Following completion of our acquisition of PRA Health Sciences on July 1, 2021, new revenue and EPS guidance is issued including PRA Health Sciences for quarters 3 and 4. Full year 2021 revenue guidance issued in the range of $5,300 - $5,500 million, representing a year over year increase of 89.5% - 96.6%. Full year 2021 adjusted earnings per share guidance issued in the range of $9.10 - $9.50, representing a year over year increase of 39.4% - 45.5%. Adjusted earnings per share to exclude amortization, stock compensation and transaction-related / integration-related costs. *before transaction-related costs and integration-related costs. DUBLIN--(BUSINESS WIRE)-- ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organisation, today reported its financial results for the second quarter ended June 30, 2021. CEO Dr. Steve Cutler commented, “ICON’s quarter 2 results show continuing progress and represent a strong platform for sustained future growth. During the quarter, ICON’s net business wins were a record $1,106 million, representing a robust book to bill of 1.27. We grew our backlog 13% year over year to $10.2 billion, revenue grew 40.5% to $871 million and adjusted earnings per share increased 76.8% year over year to $2.12. As announced on 1st July, ICON’s acquisition of PRA brings together two complementary organisations to create a world leading healthcare intelligence and clinical CRO. We expect to create significant long-term shareholder value by combining revenue growth from enhanced service offerings, innovative solutions and increased scale with our best in class global support services model. As a result of this acquisition we are updating our 2021 outlook with revenue guidance in the range of $5,300 - $5,500 million and adjusted earnings per share guidance in the range of $9.10 - $9.50.” Second Quarter 2021 Results Gross business wins in the second quarter were $1,316 million and cancellations were $210 million. This resulted in net business wins of $1,106 million and a book to bill of 1.27. Reported revenue for Quarter 2 was $871.2 million. This represents a year on year increase of 40.5% or 37.5% on a constant currency basis. US GAAP income from operations amounted to $112.9 million or 13.0% of revenue, a year on year increase of 98.2%. Adjusted income from operations* in the quarter was $132.9 million or 15.3% of revenue compared to $75.0 million or 12.1% of revenue for Quarter 2 2020. This represents a year on year increase of 77.1%. US GAAP net income attributable to the Group was $73.9 million or 8.5% of revenue. Adjusted net income* attributable to the Group for the quarter was $113.2 million or 13.0% of revenue compared with $63.6 million or 10.3% of revenue in Quarter 2 2020. This represents year on year growth of 78.0%. US GAAP earnings per share attributable to the Group on a diluted basis was $1.38 compared to $0.90 per share for the equivalent prior year period, an increase of 53.3%. Adjusted earnings per share* attributable to the Group on a diluted basis was $2.12, compared to $1.20 per share for Quarter 2 2020. This represents a year on year increase of 76.8%. Quarter 2 earnings per share excluding amortization, stock compensation and transaction-related / integration-related costs was $2.27. During the quarter the company recorded $42.1 million of transaction-related/ integration-related costs. On a comparative basis, non-GAAP days sales outstanding were 35 days at June 30, 2021, compared with 39 days at the end of March 2021 and 53 days at the end of June 2020. Cash generated from operating activities for the quarter was $128.4 million. During the quarter, $12.9 million was spent on capital expenditure. As a result, at June 30, 2021 the Group had net cash of $707.2 million, compared to net cash of $595.6 million at March 31, 2021 and $244.0 million at the end of June 2020. Year to date 2021 Results Gross business wins year to date were $2,611 million and cancellations were $404 million. This resulted in net business wins of $2,206 billion and a book to bill of 1.28. Year to date reported revenue was $1,729.4 million. This represents a year on year increase of 29.5% or 27.0% on a constant currency basis. US GAAP income from operations year to date amounted to $228.9 million or 13.2% of revenue. Adjusted income from operations* year to date was $261.4 million or 15.1% of revenue compared to $181.3 million or 13.6% of revenue for Quarter 2 2020. This represents a year on year increase of 44.2%. US GAAP net income attributable to the Group year to date was $171.0 million or 9.9% of revenue. Adjusted net income* attributable to the Group year to date was $222.8 million or 12.9% of revenue compared with $155.3 million or 11.6% of revenue in Quarter 2 2020. This represents year on year growth of 43.5%. US GAAP earnings per share attributable to the Group on a diluted basis year to date was $3.21 compared to $2.51 per share for the equivalent prior year period. Adjusted earnings per share* attributable to the Group on a diluted basis year to date was $4.18, compared to $2.89 per share for Quarter 2 2020. This represents a year on year increase of 44.6%. Year to date earnings per share excluding amortization, stock compensation and transaction-related / integration-related costs was $4.46. * before transaction-related costs and integration-related costs. Second Quarter 2021 Results for PRA Health Sciences, Inc. and Subsidiaries Net new business for PRA’s Clinical Research segment for the three months ended June 30, 2021 including reimbursement revenue was approximately $1,191 million, representing a net book-to-bill of 1.21 for the period. For the three months ended June 30, 2021, revenue was approximately $1,047 million, which represents an increase of 43.5% compared to the three months ended June 30, 2020. GAAP net income was approximately $71 million for the three months ended June 30, 2021, or $1.06 per share on a diluted basis, compared to GAAP net income of $13.9 million for the three months ended June 30, 2020, or $0.22 per share on a diluted basis. Adjusted net income was approximately $96 million for the three months ended June 30, 2021, representing an increase of 73.6% compared to the three months ended June 30, 2020. Adjusted earnings per share was approximately $1.43 for the three months ended June 30, 2021, representing an increase of 66.6% compared to the three months ended June 30, 2020. Days sales outstanding (DSO) was approximately 14 days at June 30, 2021. Other Information In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release contains certain non-GAAP financial measures, including non-GAAP operating and net income and non-GAAP diluted earnings per share. Non-GAAP operating and net income and non-GAAP diluted earnings per share exclude transaction-related costs. While non-GAAP financial measures are not superior to or a substitute for the comparable GAAP measures, ICON believes certain non-GAAP information is useful to investors for historical comparison purposes. Adjusted earnings per share attributable to the Group (Non-GAAP) has been computed by dividing non-GAAP net income attributable to the Group by the weighted average number of shares outstanding. GAAP earnings per share attributable to the Group has been computed by dividing net income attributable to the Group plus a GAAP charge associated with non-controlling interest in MeDiNova Research (“MeDiNova”) by the weighted average number of shares outstanding. ICON purchased a majority shareholding in MeDiNova on May 23, 2019. ICON exercised its call on the outstanding shares in MeDiNova and derecognized the non-controlling interest effective from March 2020. For guidance purposes adjusted earnings per share excludes amortization, stock compensation and transaction-related / integration-related costs. ICON will hold a conference call tomorrow, July 22nd, 2021 at 09:00 EDT [14:00 Ireland & UK]. This call and linked slide presentation can be accessed live from our website at http://investor.iconplc.com. A recording will also be available on the website for 90 days following the call. In addition, a calendar of company events, including upcoming conference presentations, is available on our website, under “Investors”. This calendar will be updated regularly. This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, the impact of COVID-19 on our business, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, F-4, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov. ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 16,480 employees in 89 locations in 45 countries as at June 30, 2021. For further information about ICON, visit: www.iconplc.com and www.iconplc.com/pra. Source: ICON plc Contact: Investor Relations +1888 381 7923 or Brendan Brennan Chief Financial Officer +353 1 291 2000 Jonathan Curtain Vice President Corporate Finance and Investor Relations +353 1 291 2000 All at ICON. ICON plc Condensed Consolidated Statements of Operations (US GAAP) Three and Six Months ended June 30, 2021 and June 30, 2020 (Dollars, in thousands, except share and per share data) (Unaudited) Three Months Ended Six Months Ended June June June June 30, 2021 30, 2020 30, 2021 30, 2020 Revenue 871,155 620,228 1,729,353 1,335,330 Costs and expenses: Direct costs (631,123) (445,833) (1,257,367) (951,126) Selling, general and administrative expense (109,884) (83,499) (208,419) (170,695) Depreciation and amortization (17,276) (15,858) (34,681) (32,180) Restructuring costs - (18,089) - (18,089) Total costs and expenses (758,283) (563,279) (1,500,467) (1,172,090) Income from operations 112,872 56,949 228,886 163,240 Net interest expense (24,365) (2,779) (26,835) (4,151) Income before provision for income taxes 88,507 54,170 202,051 159,089 Provision for income taxes (14,133) (6,410) (30,281) (19,000) Income before share of earnings from equity method investments 74,374 47,760 171,770 140,089 Share of equity method investments (509) - (783) - Net income 73,865 47,760 170,987 140,089 Net income attributable to non-controlling interest - - - (633) Net income attributable to the Group 73,865 47,760 170,987 139,456 Net income per Ordinary Share attributable to the Group: Basic $1.40 $0.91 $3.23 $2.55 Diluted $1.38 $0.90 $3.21 $2.51 Weighted average number of Ordinary Shares outstanding: Basic 52,909,368 52,570,104 52,860,414 52,959,229 Diluted 53,381,501 53,028,567 53,294,435 53,691,138 (Non-GAAP) Three and Six Months ended June 30, 2021 and June 30, 2020 (Dollars, in thousands, except share and per share data) (Unaudited) Three Months Ended Six Months Ended June June June June 30, 2021 30, 2020 30, 2021 30, 2020 Revenue 871,155 620,228 1,729,353 1,335,330 Costs and expenses: Direct costs (631,123) (445,833) (1,257,367) (951,126) Selling, general and administrative expense (89,867) (83,499) (175,901) (170,695) Depreciation and amortization (17,276) (15,858) (34,681) (32,180) Total costs and expenses (738,266) (545,190) (1,467,949) (1,154,001) Income from operations 132,889 75,038 261,404 181,329 Net interest expense (2,240) (2,779) (4,357) (4,151) Income before provision for income taxes 130,649 72,259 257,047 177,178 Provision for income taxes (16,984) (8,671) (33,416) (21,261) Income before share of earnings from equity method investments 113,665 63,588 223,631 155,917 Share of equity method investments (509) - (783) - Net income 113,156 63,588 222,848 155,917 Net income attributable to non-controlling interest - - - (633) Net income attributable to the Group 113,156 63,588 222,848 155,284 Adjusted net income per Ordinary Share attributable to the Group: Adjusted basic (non-GAAP) $2.14 $1.21 $4.22 $2.93 Adjusted diluted (non-GAAP) $2.12 $1.20 $4.18 $2.89 Weighted average number of Ordinary Shares outstanding: Basic 52,909,368 52,570,104 52,860,414 52,959,229 Diluted 53,381,501 53,028,567 53,294,435 53,691,138 ICON plc Summary Consolidated Balance Sheet Data June 30, 2021 and March 31, 2021 (Dollars, in thousands) June 30, March 31, 2021 2021 (Unaudited) (Unaudited) Cash and short-term investments 1,057,225 944,184 Debt (350,000) (348,592) Net cash/(debt) 707,225 595,592 Net Accounts Receivable 417,403 465,585 Working Capital 1,180,347 1,088,833 Total Assets 3,584,464 3,466,576 Shareholder's Equity 2,027,943 1,934,171 PRA Health Sciences, Inc. and Subsidiaries Reconciliation of non-GAAP measures Three and Six Months ended June 30, 2021 and June 30, 2020 (Dollars, in thousands, except share and per share data) (Unaudited) Three Months Ended Six Months Ended June 30, 2021 June 30, 2020 June 30, 2021 June 30, 2020 Net income attributable to PRA Health Sciences, Inc. 71,068 13,874 128,008 54,534 (Benefit from) provision for income taxes (12,995) 7,112 6,702 23,983 Amortization of intangible assets 17,775 19,030 35,714 38,157 Amortization of deferred financing costs 422 421 842 842 Amortization of terminated interest rate swaps - 1,562 - 3,127 Stock-based compensation expense (a) 18,732 15,845 37,504 31,270 Loss (gains) on disposal of fixed assets, net (b) 14 194 138 175 Foreign currency losses (gains), net (c) 6,116 10,768 (6,272) 2,926 Other non-operating expense, net (d) (87) (23) (42) (18) Transaction-related costs (e) 23,415 - 36,852 609 Acquisition-related costs (f) - 406 - 1,245 Non-cash rent adjustment (g) (652) 1,087 (1,573) 579 Other charges (h) 764 1,469 3,028 1,750 Adjusted pre-tax income 124,572 71,745 240,901 159,179 Adjusted tax expense (i) 28,651 16,501 55,407 36,611 Adjusted net income 95,921 55,244 185,494 122,568 Diluted weighted average common shares outstanding 67,166 64,457 66,670 64,398 Adjusted net income per diluted share 1.43 0.86 2.78 1.90 a Stock-based compensation expense represents the amount of recurring non-cash expense related to the Company’s equity compensation programs. b Loss (gains) on disposal of fixed assets represents the costs incurred in connection with the sale or disposition of fixed assets, primarily IT equipment and furniture and fixtures. We exclude these losses from adjusted EBITDA and adjusted net income because they result from investing decisions rather than from decisions made related to our ongoing operations. c Foreign currency losses (gains), net primarily relates to gains or losses that arise in connection with the revaluation of short-term inter-company balances between our domestic and international subsidiaries. In addition, this amount includes gains or losses from foreign currency transactions, such as those resulting from the settlement of third-party accounts receivable and payables denominated in a currency other than the local currency of the entity making the payment. We exclude these gains and losses from adjusted EBITDA and adjusted net income because they result from financing decisions rather than from decisions made related to our ongoing operations and because fluctuations from period- to- period do not necessarily correspond to changes in our operating results. d Other non-operating expense, net represents income and expense that are non-operating and whose fluctuations from period- to- period do not necessarily correspond to changes in our operating results. e Transaction-related costs include fees associated with costs associated with acquisition related earn-out liabilities, our secondary offerings, stock-based compensation expense related to the transfer restrictions on vested options, the amendment to our accounts receivable financing agreement, and expenses associated with our acquisitions. f Acquisition-related costs primarily consist of professional fees, rebranding costs, the elimination of redundant facilities and any other costs incurred directly related to the integration of these acquisitions. g We have escalating leases that require the amortization of rent expense on a straight-line basis over the life of the lease. The non-cash rent adjustment represents the difference between rent expense recorded in the consolidated statement of operations and the amount of cash actually paid. h Represents charges incurred that are not considered part of our core operating results. i Represents the tax effect of adjusted pre-tax income at our estimated effective tax rate. ICON/ICLR-F View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005902/en/ Contact: Investor Relations +1 888 381 7923 or Brendan Brennan Chief Financial Officer +353 1 291 2000 Jonathan Curtain Vice President Corporate Finance & Investor Relations +353 1 291 2000 http://www.iconplc.com Source: ICON plc View this news release online at: http://www.businesswire.com/news/home/20210721005902/en
亮点 创纪录的净业务赢在11.06亿美元的季度,同比增长21.6%;一本网书给比尔1.27英镑。 创纪录的102亿美元结案积压,同比增长12.7%。 第二季度报告收入为8.712亿美元,同比增长40.5%,较202年第一季度增长1.5%。 经调整营业收入*为1.329亿美元,占收入的15.3%,同比增长77.1%。本集团应占经调整净收益*为1.132亿美元或每股摊薄股份2.12美元,较去年同期每股1.20美元增加76.8%。 美国通用会计准则业务收入为1.129亿美元,占收入的13.0%,同比增长98.2%。本集团应占美国通用会计准则净收益为7390万美元,或每股摊薄股份1.38美元,而去年同期为每股0.90美元,增长53.3%。 强劲的现金生成使现金头寸总额达到创纪录的10.57亿美元。截至2020年6月30日,未完成销售天数从53天减少至35天。 PRA临床研究部门第二季度包括报销收入在内的净业务收入约为11.91亿美元;一本网书给比尔1.21英镑。第二季度收入约为10.47亿美元,同比增长43.5%。 在我们于2021年7月1日完成对PRA Health Sciences的收购后,发布了新的收入和每股收益指南,包括第三季度和第四季度的PRA Health Sciences。2021年全年收入指南发布范围为5300-55亿美元,同比增长89.5%-96.6%。2021年全年调整后每股收益指引发布范围为9.10美元至9.50美元,同比增长39.4%-45.5%。经调整的每股收益,以不包括摊销、股票补偿和与交易相关/与整合相关的成本。 *在交易相关费用和整合相关费用之前。 都柏林--(商业网)--世界领先的医疗保健智能和临床研究组织ICON plc(纳斯达克代码:ICLR)今天报告了截至2021年6月30日的第二季度财务业绩。 首席执行官史蒂夫·卡特勒博士评论说:“ICON第二季度的业绩显示了持续的进步,代表了未来持续增长的强大平台。在本季度,Icon的净业务收入达到创纪录的11.06亿美元,比比尔高出1.27美元。我们的积压业务同比增长13%,至102亿美元,收入增长40.5%,至8.71亿美元,调整后每股收益同比增长76.8%,至2.12美元。 正如7月1日宣布的那样,图标对PRA的收购汇集了两个互补的组织,以创建一个世界领先的医疗保健智能和临床CRO。我们期望通过加强服务提供、创新解决方案和扩大规模带来的收入增长与我们一流的全球支持服务模式相结合,为股东创造重大的长期价值。由于这次收购,我们将更新2021年的前景,收入指导范围为5300-55亿美元,调整后的每股收益指导范围为9.10-9.50美元。“ 2021年第二季度业绩 第二季度的业务收入总额为13.16亿美元,取消额为2.1亿美元。这导致了11.06亿美元的业务净收益和1.27美元的账面收益。 第二季度报告的收入为8.712亿美元。按不变货币计算,同比增长40.5%或37.5%。 美国通用会计准则业务收入为1.129亿美元,占收入的13.0%,同比增长98.2%。经调整营业收入*于本季度为1.329亿美元,占收入的15.3%,而202年第2季度为75.0百万美元,占收入的12.1%。同比增长77.1%。 美国通用会计准则归属于该集团的净收入为7390万美元,占收入的8.5%。本集团于本季度应占经调整净收入*为11320万美元,占收入的13.0%,而202年第2季度为6360万美元,占收入的10.3%。同比增长78.0%。 美国公认会计原则摊薄后本集团每股应占盈利为1.38美元,较上年同期每股0.90美元增加53.3%。经调整每股盈利*本集团摊薄应占每股盈利为2.12美元,而202年第2季度每股盈利为1.20美元。同比增长76.8%。第二季度每股收益不包括摊销、股票补偿和交易相关/整合相关成本为2.27美元。 在本季度,该公司记录了4210万美元的交易相关/集成相关成本。比较而言,截至2021年6月30日,非公认会计准则未偿销售天数为35天,而2021年3月底为39天,2020年6月底为53天。 本季度经营活动产生的现金为1.284亿美元。季度内,1290万美元用于资本支出。因此,于2021年6月30日,本集团的现金净额为7.072亿美元,而于2021年3月31日及2020年6月底的现金净额分别为5.956亿美元及2.44亿美元。 2021年迄今业绩 今年迄今为止的商业赢利总额为26.11亿美元,取消额为4.04亿美元。这导致了22060亿美元的净营业收入和1.28美元的账面收益。 今年迄今报告的收入为17.294亿美元。按不变货币计算,同比增长29.5%或27.0%。 美国公认会计原则业务收入今年迄今为2.289亿美元,占收入的13.2%。经调整营运收入*本年度至今为2.614亿美元,占收入的15.1%,而202年第2季度为1.813亿美元,占收入的13.6%。同比增长44.2%。 本集团本年度至今归属于美国公认会计原则的净收入为1.71亿美元,占收入的9.9%。本集团本年度至今应占经调整净收入*为2.228亿美元,占收入的12.9%,而202年第2季度为1.553亿美元,占收入的11.6%。同比增长43.5%。 本集团应占美国公认会计原则每股摊薄盈利为3.21美元,而上一年度同期为2.51美元。经调整每股盈利*本集团经摊薄应占年度至今每股盈利为4.18美元,而202年第2季度每股盈利为2.89美元。同比增长44.6%。年初至今,不包括摊销、股票补偿和交易相关/整合相关成本的每股收益为4.46美元。 *在交易相关费用和整合相关费用之前。 PRA健康科学公司及其子公司2021年第二季度业绩 截至2021年6月30日止三个月,PRA临床研究分部的净新业务包括报销收入约为11.91亿美元,即期内净账面对账单为1.21。 截至2021年6月30日止三个月,收入约为10.47亿美元,较截至2020年6月30日止三个月增长43.5%。 截至2021年6月30日止三个月的GAAP净收入约为7100万美元,摊薄后每股1.06美元,而截至2020年6月30日止三个月的GAAP净收入为1390万美元,摊薄后每股0.22美元。 截至2021年6月30日止三个月,经调整净收入约为9,600万美元,较截至2020年6月30日止三个月增加73.6%。截至2021年6月30日止三个月,经调整每股盈利约为1.43美元,较截至2020年6月30日止三个月增加66.6%。 截至2021年6月30日,未偿销售天数(DSO)约为14天。 其他资料 除了根据公认会计原则(GAAP)编制的财务措施外,本新闻稿还包含某些非公认会计原则的财务措施,包括非公认会计原则的经营和净收入以及非公认会计原则的每股摊薄收益。非公认会计原则的营业和净收入以及非公认会计原则的每股摊薄收益不包括与交易相关的成本。虽然非公认会计原则的财务衡量标准并不优于或替代可比的公认会计原则衡量标准,但ICON认为某些非公认会计原则的信息对于投资者的历史比较是有用的。 本集团应占经调整每股盈利(非公认会计原则)乃按本集团应占非公认会计原则净收入除以加权平均已发行股份数计算。本集团应占每股公认会计原则盈利乃按本集团应占净收入加上与MeDiNova Research(“MeDiNova”)非控股权有关的公认会计原则费用除以已发行股份的加权平均数计算。ICON于2019年5月23日购买了MeDiNova的多数股权。ICON行使了对MeDiNova已发行股份的呼吁,并自2020年3月起终止确认非控股权。 为指导目的,调整后每股收益不包括摊销、股票补偿和与交易相关/与整合相关的成本。 ICON将于明天,2021年7月22日美国东部时间09:00(爱尔兰和英国14:00)举行电话会议。我们的网站http://investor.iconplc.com可以实时访问这个电话和链接的幻灯片演示文稿。通话后90天内,网站上还将提供录音。此外,公司活动日历,包括即将举行的会议介绍,可在我们的网站“投资者”下查阅。本日历将定期更新。 本新闻稿包含前瞻性陈述。这些陈述是基于管理层目前的预期和现有信息,包括当前的经济和行业状况。这些声明不是对未来业绩或实际结果的保证,实际结果、发展和商业决策可能与本新闻稿中的声明不同。前瞻性陈述受未来事件的影响,风险,不确定因素和其他可能导致实际结果与报表中预测的结果大不相同的因素,包括但不限于订立新合约、维持客户关系、管理开设新办事处及提供新服务的能力、整合新业务合并及收购、新冠肺炎对我们业务的影响,以及ICON提交的SEC报告中不时详述的其他经济及全球市场状况及其他风险及不确定性,所有这些都难以预测,部分亦超出我们的控制范围。由于这些原因,你在作出投资决定时不应过分依赖这些前瞻性陈述。“预期”一词以及这些词的变体和类似的表述旨在识别前瞻性陈述。前瞻性陈述仅限于其发表之日,我们不承担任何义务公开更新任何前瞻性陈述,无论是由于新信息、未来事件还是其他原因。有关与这些前瞻性陈述有关的风险和不确定性的更多信息可在ICON提交的SEC报告中找到,包括其表格20-F、F-1、F-4、S-8和F-3,这些报告可在SEC网站http://www.SEC.gov上查阅。 ICON plc是一家世界领先的医疗保健智能和临床研究机构。从分子到药物,我们推进临床研究,为制药、生物技术、医疗器械以及政府和公共卫生组织提供外包服务。我们开发新的创新,推动新兴疗法向前发展,改善患者生活。ICON总部位于爱尔兰都柏林,截至2021年6月30日,该公司在45个国家的89个地点雇佣了约16,480名员工。欲了解有关ICON的更多信息,请访问:www.iconplc.com和www.iconplc.com/pra。 来源:ICON plc 联系方式:投资者关系+1888 381 792 3或 布伦丹·布伦南首席财务官+353 1 291 2000 0 乔纳森·科伦副总裁企业融资和投资者关系+353 1 291 2000 0 都在图标。 ICON plc 简明综合经营报表 (美国公认会计原则) 截至2021年6月30日和2020年6月30日的三个月和六个月 (美元,以千为单位,股份和每股数据除外) (未经审计) 三个月结束 六个月结束 六月 六月 六月 六月 2021年30 30、2020 2021年30 30、2020 收入 871,155 620,228 1,729,353 1,335,330 成本和费用: 直接成本 (631,123) (445,833) (1,257,367) (951,126) 销售、一般和行政费用 (109,884) (83,499) (208,419) (170,695) 折旧和摊销 (17,276) (15,858) (34,681) (32,180) 重组费用 - (18,089) - (18,089) 成本和费用共计 (758,283) (563,279) (1,500,467) (1,172,090) 业务收入 112,872 56,949 228,886 163,240 净利息费用 (24,365) (2,779) (26,835) (4,151) 所得税拨备前的收入 88,507 54,170 202,051 159,089 所得税准备金 (14,133) (6,410) (30,281) (19,000) 权益法投资收益前的收益 74,374 47,760 171,770 140,089 权益法投资份额 (509) - (783) - 净收入 73,865 47,760 170,987 140,089 非控股权应占净收益 - - - (633) 本集团应占净收入 73,865 47,760 170,987 139,456 本集团应占每股普通股净收益: 基本 1.40美元 0.91美元 3.23美元 2.55美元 稀释的 1.38美元 0.90美元 3.21美元 2.51美元 已发行普通股加权平均数: 基本 52,909,368 52,570,104 52,860,414 52,959,229 稀释的 53,381,501 53,028,567 53,294,435 53,691,138 (非公认会计原则) 截至2021年6月30日和2020年6月30日的三个月和六个月 (美元,以千为单位,股份和每股数据除外) (未经审计) 三个月结束 六个月结束 六月 六月 六月 六月 2021年30 30、2020 2021年30 30、2020 收入 871,155 620,228 1,729,353 1,335,330 成本和费用: 直接成本 (631,123) (445,833) (1,257,367) (951,126) 销售、一般和行政费用 (89,867) (83,499) (175,901) (170,695) 折旧和摊销 (17,276) (15,858) (34,681) (32,180) 成本和费用共计 (738,266) (545,190) (1,467,949) (1,154,001) 业务收入 132,889 75,038 261,404 181,329 净利息费用 (2,240) (2,779) (4,357) (4,151) 所得税拨备前的收入 130,649 72,259 257,047 177,178 所得税准备金 (16,984) (8,671) (33,416) (21,261) 权益法投资收益前的收益 113,665 63,588 223,631 155,917 权益法投资份额 (509) - (783) - 净收入 113,156 63,588 222,848 155,917 非控股权应占净收益 - - - (633) 本集团应占净收入 113,156 63,588 222,848 155,284 本集团应占每股普通股经调整净收益: 经调整的基本原则(非公认会计原则) 2.14美元 1.21美元 4.22美元 2.93美元 经调整的稀释(非公认会计原则) 2.12美元 1.20美元 4.18美元 2.89美元 已发行普通股加权平均数: 基本 52,909,368 52,570,104 52,860,414 52,959,229 稀释的 53,381,501 53,028,567 53,294,435 53,691,138 ICON plc 汇总合并资产负债表数据 2021年6月30日、2021年3月31日 (美元,单位:千) 6月30日, 3月31日, 2021 2021 (未经审计) (未经审计) 现金和短期投资 1,057,225 944,184 债务 (350,000) (348,592) 现金/(债务)净额 707,225 595,592 应收账款净额 417,403 465,585 营运资金 1,180,347 1,088,833 总资产 3,584,464 3,466,576 股东权益 2,027,943 1,934,171 PRA健康科学公司及其子公司 非公认会计原则措施的协调 截至2021年6月30日和2020年6月30日的三个月和六个月 (美元,以千为单位,股份和每股数据除外) (未经审计) 三个月 已结束 六个月 已结束 六月 2021年30 六月 30、2020 六月 2021年30 六月 30、2020 PRA Health Sciences,Inc.应占净收入。 71,068 13,874 128,008 54,534 (受益于)所得税准备金 (12,995) 7,112 6,702 23,983 无形资产摊销 17,775 19,030 35,714 38,157 递延融资成本摊销 422 421 842 842 终止利率掉期的摊销 - 1,562 - 3,127 以股票为基础的补偿费用(a) 18,732 15,845 37,504 31,270 处置固定资产损失(利得),净额(b) 14 194 138 175 外币损失(收益),净额(c) 6,116 10,768 (6,272) 2,926 其他营业外费用净额(d) (87) (23) (42) (18) 与交易有关的费用(e) 23,415 - 36,852 609 与购置有关的费用(f) - 406 - 1,245 非现金租金调整(g) (652) 1,087 (1,573) 579 其他费用(h) 764 1,469 3,028 1,750 调整税前收入 124,572 71,745 240,901 159,179 调整后的税项支出(一) 28,651 16,501 55,407 36,611 调整后净收入 95,921 55,244 185,494 122,568 已发行普通股摊薄加权平均数 67,166 64,457 66,670 64,398 经调整后每股摊薄股份净收益 1.43 0.86 2.78 1.90 a 以股票为基础的补偿费用指与本公司权益补偿计划有关的经常性非现金费用金额。 b 处置固定资产损失(收益)指出售或处置固定资产(主要为资讯科技设备、家具及固定装置)所产生的成本。我们将该等亏损从经调整EBITDA及经调整净收益中剔除,因为该等亏损源自投资决策,而非与我们持续经营有关的决策。 c 外币亏损(利得)净额主要与重估本公司国内及国际附属公司之间的短期公司间结馀而产生的利得或亏损有关。此外,这一数额包括外币交易的损益,例如以付款实体当地货币以外的货币结算第三方应收账款和应付账款所产生的损益。我们将该等损益从经调整EBITDA及经调整净收益中剔除,因为该等损益源自融资决策,而非与本公司持续经营相关的决策,亦因为各期间的波动未必与本公司经营业绩的变动相对应。 D 其他营业外费用净额指非营业收入及费用,其期间变动未必与经营业绩变动相符。 e 与交易相关的成本包括与收购相关的盈利负债相关的成本相关的费用、我们的第二次发行、与既得期权的转让限制相关的基于股票的补偿费用、我们的应收账款融资协议的修订以及与我们的收购相关的费用。 f 与购置有关的费用主要包括专业人员费用、品牌重塑费用、消除多余设施以及与合并这些购置直接有关的任何其他费用。 g 我们有不断升级的租赁,要求在租赁期内按直线法摊销租金费用。非现金租金调整指于综合经营报表内记录的租金开支与实际支付的现金金额之间的差额。 h 指不被视为核心经营业绩一部分的已发生费用。 我 表示按估计实际税率计算的经调整税前收入的税务影响。 ICON/ICLR-F 在businesswire.com查看源代码版本:https://www.businesswire.com/news/home/20210721005902/en/ 联系人: 投资者关系+1 888 381 792 3或 布伦丹·布伦南首席财务官+353 1 291 2000 0 乔纳森·科伦副总裁企业融资和投资者关系+353 1 291 2000 0 http://www.iconplc.com 来源:ICON plc 在网上查看此新闻稿: http://www.businesswire.com/news/home/20210721005902/en

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文